Alex del Rosario, MD
Psychiatry · Las Vegas, NVNPI 1336248145
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 483 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,701, 5.0 times the $539 reported in 2019. Among psychiatry clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 483 payments — averaging $18.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Alkermes, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Neurocrine Biosciences, Inc.$755
- Lundbeck LLC$503
- plus $3K from 20 others
What the payments were for
- Food & beverage$8,791100%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 83 | $1,364 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 80 | $1,186 |
| Alkermes, Inc. | 56 | $1,185 |
| Otsuka America Pharmaceutical, Inc. | 70 | $1,089 |
| Neurocrine Biosciences, Inc. | 40 | $755 |
| Lundbeck LLC | 26 | $503 |
| Johnson & Johnson | 24 | $380 |
| E.r. Squibb & Sons, L.L.C. | 19 | $373 |
| Vanda Pharmaceuticals Inc. | 14 | $364 |
| Almatica Pharma LLC | 16 | $364 |
| Idorsia Pharmaceuticals US Inc | 16 | $301 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $153 |
| EMD Serono, Inc. | 1 | $135 |
| Axsome Therapeutics, Inc. | 4 | $99 |
| Inspire Medical Systems, Inc. | 1 | $84 |
| Eisai Inc. | 4 | $83 |
| Merck | 5 | $73 |
| Bausch Health US, LLC | 3 | $53 |
| Shire North American Group Inc | 3 | $48 |
| Avanir Pharmaceuticals, Inc. | 2 | $44 |
| Teva Pharmaceuticals USA, Inc. | 2 | $41 |
| Janssen Scientific Affairs, LLC | 1 | $35 |
| Sage Therapeutics, LLC | 2 | $33 |
| Indivior Inc. | 1 | $20 |
| Corium, LLC | 1 | $20 |
| Ironshore Pharmaceuticals Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SEROSTIM$135
How this compares
$8,807 in reported general payments places this provider in the 90th percentile of 243 psychiatry providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 72 | $201,071 |
| VraylarCariprazine Hcl | 91 | $133,117 |
| IngrezzaValbenazine Tosylate | 13 | $96,378 |
| Abilify MaintenaAripiprazole | 30 | $84,220 |
| RexultiBrexpiprazole | 36 | $74,612 |
| CaplytaLumateperone Tosylate | 27 | $46,599 |
| TrintellixVortioxetine Hydrobromide | 50 | $36,083 |
| Lurasidone Hcl | 123 | $28,291 |
| Aripiprazole | 238 | $26,375 |
| LybalviOlanzapine/Samidorphan Malate | 11 | $19,879 |
| BelsomraSuvorexant | 36 | $15,646 |
| QuviviqDaridorexant Hcl | 30 | $14,818 |
| AmbienZolpidem Tartrate | 12 | $7,665 |
| Quetiapine Fumarate | 505 | $7,405 |
| Ziprasidone Hcl | 122 | $6,610 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $380 | $201,07172 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,089 | $158,83266 claims |
| AbbVieVraylar, Fetzima | $1,364 | $139,719105 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $755 | $96,37813 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,186 | $46,59927 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $153 | $36,08350 claims |
| Alkermes, Inc.Lybalvi | $1,185 | $19,87911 claims |
| MerckBelsomra | $73 | $15,64636 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $301 | $14,81830 claims |
| Almatica Pharma LLCSertraline Hcl | $364 | $1,674327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 243 psychiatry providers in Nevada.
Other psychiatry in Las Vegas
- Jelena KunovacLas Vegas$1.2M
- John AnooshianLas Vegas$836K
- Sam ZandLas Vegas$410K
- Aaron RitterLas Vegas$173K
- Mustafa RawafLas Vegas$166K
- Dylan WintLas Vegas$86K
- Mujeeb ShadLas Vegas$55K
- Dax WolfordLas Vegas$29K
- Faisal SubaLas Vegas$15K
- Ejine OkoroaforLas Vegas$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.